2 unknown. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Unknown 2 |
Follow Prostate Cancer Recurrent: new trials by email Literature Review of Prostate Cancer Recurrent trials Research Report on Prostate Cancer Recurrent
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MBM-02 (Tempol) for the Treatment of Biochemical Recurrent Prostate Cancer MBM-02 - Prostate Cancer Recurrent, Biochemical Recurrent Prostate Cancer | Phase 2 | Unknown | Matrix Biomed, Inc. | 55 | 2021-05-30 | 2021-05-06 |
| Stereotactic Body Radiotherapy With or Without Darolutamide for OligoRecurrent Prostate Cancer Darolutamide, metastasis-directed treatment - Prostate Cancer, Prostate Cancer Recurrent | Phase 2 | Unknown | University Hospital, Ghent | 124 | 2021-02-12 | 2024-02-28 |
Neoplasm Metastasis (1) · Prostatic Neoplasms (1)
Genital Diseases (1) · Genital Diseases, Male (1) · Genital Neoplasms, Male (1) · Male Urogenital Diseases (1) · Neoplasms (1) · Neoplasms by Site (1) · Neoplastic Processes (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · Prostatic Diseases (1) · Urogenital Diseases (1) · Urogenital Neoplasms (1)
TEMPOL-H (1) · darolutamide (1) · tempol (1)
Matrix Biomed, Inc. (1) · University Hospital, Ghent (1)
Belgium (1) · United States (1)